Blockade of the KATP channel Kir6.2 by memantine represents a novel mechanism relevant to Alzheimer's disease therapy.
about
Pharmacokinetic Properties of Memantine after a Single Intraperitoneal Administration and Multiple Oral Doses in Euploid Mice and in the Ts65Dn Mouse Model of Down's Syndrome.Reduced CaM Kinase II and CaM Kinase IV Activities Underlie Cognitive Deficits in NCKX2 Heterozygous Mice.Subclinical Doses of ATP-Sensitive Potassium Channel Modulators Prevent Alterations in Memory and Synaptic Plasticity Induced by Amyloid-β.Spatial recognition test: A novel cognition task for assessing topographical memory in mice.Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome.Memantine has no effect on K channels in pancreatic β cells
P2860
Blockade of the KATP channel Kir6.2 by memantine represents a novel mechanism relevant to Alzheimer's disease therapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Blockade of the KATP channel K ...... o Alzheimer's disease therapy.
@en
Blockade of the KATP channel K ...... o Alzheimer's disease therapy.
@nl
type
label
Blockade of the KATP channel K ...... o Alzheimer's disease therapy.
@en
Blockade of the KATP channel K ...... o Alzheimer's disease therapy.
@nl
prefLabel
Blockade of the KATP channel K ...... o Alzheimer's disease therapy.
@en
Blockade of the KATP channel K ...... o Alzheimer's disease therapy.
@nl
P2093
P2860
P356
P1433
P1476
Blockade of the KATP channel K ...... to Alzheimer's disease therapy
@en
P2093
H Sakagami
H Tagashira
K Fukunaga
S Moriguchi
T Narahashi
P2860
P2888
P304
P356
10.1038/MP.2016.187
P407
P50
P577
2016-10-25T00:00:00Z